Clinical trials: Ovarian Epithelial Cancer
Ovarian Cancer, Head and Neck Cancer
A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors
This is a multicenter, open label, Phase 2 study of TJ004309 in combination with atezolizumab in patients with advanced or metastatic solid tumors.
- Conditions
- Ovarian Cancer, Head and Neck Cancer, Non Small Cell Lung Cancer, Gastrointestinal Cancer
- Trial name
- NCT05001347
- Testing
- TJ004309
- Where
- 15 sites in United States
- Volunteers
- 25 people
- Sponsor
- I-Mab Biopharma US Limited
Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
This phase II trial studies the possible benefits of treatment with different combinations of the drugs durvalumab, olaparib and cediranib vs.
- Conditions
- Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma
- Trial name
- NCT04739800
- Testing
- Biospecimen Collection, Cediranib Maleate, Computed Tomography
- Where
- 391 sites in United States, Puerto Rico
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Adavosertib in combination with carboplatin, paclitaxel, gemcitabine, or PLD.
- Trial name
- NCT02272790
- Testing
- Adavosertib, Paclitaxel, Carboplatin
- Where
- 20 sites in United States, Canada and 1 more
- Volunteers
- 95 people
- Sponsor
- AstraZeneca
Epithelial Ovarian Cancer, Peritoneal Cancer
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression
This Phase 3 study is designed to compare the efficacy and safety of mirvetuximab soravtansine (MIRV) vs. IC chemotherapy in participants with platinum-resistant high-grade epithelial ovarian cancer, primary peritoneal, or…
- Conditions
- Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- MIRASOL (NCT04209855)
- Testing
- Mirvetuximab Soravtansine, Paclitaxel, Topotecan
- Where
- 214 sites in United States, Australia and 19 more
- Volunteers
- 453 people
- Sponsor
- AbbVie
Fallopian Tube Cancer, Ovarian Cancer
Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Ovarian cancer is a leading cause of cancer death in women. Monocytes are white blood cells that slow tumor growth. Interferons (IFNs) are molecules that help immune cells fight cancer.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT02948426
- Testing
- Autologous Monocytes + ACTIMMUNE + SYLATRON
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Ovarian Cancer, Metastatic Fallopian Tube Cancer
T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer
Although immunotherapy has revolutionized the treatment of many cancers, ovarian cancer patients have not yet benefitted from the advances.
- Conditions
- Metastatic Ovarian Cancer, Metastatic Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT04611126
- Testing
- Ipilimumab, Cyclophosphamid, Fludarabine Phosphate
- Where
- Denmark
- Volunteers
- 6 people
- Sponsor
- Inge Marie Svane
Locally Advanced or Metastatic Solid Tumor
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
This is an open-label Phase 1b/2 multicenter study of rebastinib (DCC-2036) in combination with carboplatin designed to evaluate the safety, tolerability, and pharmacokinetics (PK) in participants with advanced or metastatic…
- Trial name
- NCT03717415
- Testing
- Rebastinib, Carboplatin
- Where
- 9 sites in United States
- Volunteers
- 70 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
SL03-OHD-105 is an open-label, multicenter, phase 1b trial designed to evaluate SL-172154 administered in combination with pegylated liposomal doxorubicin (PLD) or mirvetuximab soravtansine (MIRV) in patients with platinum…
- Conditions
- Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer
- Trial name
- NCT05483933
- Testing
- Pegylated Liposomal Doxorubicin + SL-172154, Mirvetuximab + SL-172154
- Where
- 21 sites in United States, Canada and 2 more
- Volunteers
- 86 people
- Sponsor
- Shattuck Labs, Inc.
Cancer
Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant
RATIONALE: Antiemetic drugs, such as aprepitant, ondansetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients undergoing a stem cell transplant.
- Trial name
- NCT00248547
- Testing
- aprepitant, dexamethasone, ondansetron
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- OHSU Knight Cancer Institute
Ovarian Carcinoma
Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy
This randomized pilot early phase I trial studies how well denosumab works in BRCA1/2 mutations carriers scheduled for risk-reducing salpingo-oophorectomy.
- Trial name
- NCT03382574
- Testing
- Denosumab, Salpingo-Oophorectomy
- Where
- 6 sites in United States, Israel
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Ovarian Cancer
FPA150 in Patients With Advanced Solid Tumors
This is a multi-center study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of FPA150, an anti-B7H4 antibody alone or in combination with pembrolizumab an anti-PD1…
- Conditions
- Breast Cancer, Ovarian Cancer, Endometrial Cancer, Advanced Solid Tumors
- Trial name
- FPA150-001 (NCT03514121)
- Testing
- FPA150, Pembrolizumab
- Where
- 18 sites in United States, South Korea
- Volunteers
- 95 people
- Sponsor
- Five Prime Therapeutics, Inc.
Ovarian Cancer
AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
This randomized, open-label, 2-arm study will evaluate the efficacy and safety of Avastin added to chemotherapy versus chemotherapy alone in patients with epithelial ovarian, fallopian tube or primary peritoneal cancer with…
- Trial name
- NCT00976911
- Testing
- Bevacizumab, liposomal doxorubicin, paclitaxel
- Where
- 117 sites in Belgium, Bosnia and Herzegovina and 12 more
- Volunteers
- 361 people
- Sponsor
- Hoffmann-La Roche
Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer
Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
This phase II trial is studying how well eribulin mesylate works in treating patients with recurrent ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer.
- Conditions
- Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
- Trial name
- NCT00334893
- Testing
- eribulin mesylate
- Where
- 2 sites in United States
- Volunteers
- 74 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Neoplasms, Ascites
Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites
This study was designed to characterize the effect of aflibercept in participants with advanced chemoresistant ovarian cancer. Primary objective: Compare the effect of aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)…
- Trial name
- NCT00327444
- Testing
- aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
- Where
- 9 sites in United States, Austria and 7 more
- Volunteers
- 58 people
- Sponsor
- Sanofi
Primary Peritoneal Carcinoma, Tumor
Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors
This is an open-label, two-arm, multicenter feasibility study to evaluate the safety and tolerability of pazopanib in combination with carboplatin and paclitaxel in female subjects with newly diagnosed advanced gynaecological…
- Conditions
- Primary Peritoneal Carcinoma, Tumor, Epithelial Ovarian Cancer, Uterine Disease
- Trial name
- NCT00561795
- Testing
- pazopanib (GW786034), carboplatin, paclitaxel
- Where
- 5 sites in France, Germany
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
Ovarian Carcinoma, Primary Peritoneal Carcinoma
Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma
The purpose of this study is to determine if the combination of bevacizumab and pemetrexed have an effect on recurrent ovarian and primary peritoneal carcinoma by looking at progression and survival at 6 months.
- Trial name
- NCT00868192
- Testing
- Pemetrexed, Bevacizumab
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Washington University School of Medicine
Advanced Epithelial Ovarian, Recurrent Epithelial Ovarian
Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
This is a Phase II study. The purpose of this study is to find out what effects, good and/or bad enzalutamide has on the patient and the cancer. All patients who enter the study will be closely monitored for side-effects.
- Conditions
- Advanced Epithelial Ovarian, Recurrent Epithelial Ovarian, Fallopian Tube, Primary Peritoneal Carcinoma
- Trial name
- NCT01974765
- Testing
- Enzalutamide
- Where
- 6 sites in United States
- Volunteers
- 59 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian Cancer
Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study)
This research study is studying a combination of two drug interventions called rosuvastatin and enoxaparin as a possible preventative measure against developing venous blood clots (such deep vein thrombosis or pulmonary…
- Trial name
- NCT03532139
- Testing
- Enoxaparin, Enoxaparin + Rosuvastatin, Thromboprophylaxis
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Beth Israel Deaconess Medical Center
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab
This is a randomized, two-arm, open-label Phase II multicenter study designed to examine the effects of adding bevacizumab to ixabepilone for the treatment of patients who have recurrent or persistent…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT03093155
- Testing
- Ixabepilone, Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 78 people
- Sponsor
- Yale University
Ovarian Cancer, Ovarian Neoplasms
Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer
The main purpose of this study is to validate a safe dose of atezolizumab with dose-dense paclitaxel and carboplatin when utilized with neoadjuvant chemotherapy and interval cytoreductive surgery followed by maintenance…
- Trial name
- AdORN (NCT03394885)
- Testing
- Atezolizumab, Carboplatin, Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Duke University